The company's biomaterials are made from plant-derived cellulose and offer new avenues in regenerative medicine. Spiderwort's scaffold architectures are highly biocompatible and induce angiogenesis, making them suitable for spinal cord injury repair and soft tissue regeneration. Although the product is still in the pre-clinical stage, the promising results demonstrate the potential of this novel biomaterial to revolutionize regenerative medicine.